personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Company profile
Ticker
PSNL
Exchange
Website
CEO
John West
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Personalis (UK) Ltd. • Shanghai Personalis Biotechnology Co., Ltd. ...
IRS number
275411038
PSNL stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
2 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
EFFECT
Notice of effectiveness
10 Jan 24
EFFECT
Notice of effectiveness
9 Jan 24
8-K
Personalis Reports Preliminary Fourth Quarter and Full
5 Jan 24
CORRESP
Correspondence with SEC
5 Jan 24
Transcripts
PSNL
Earnings call transcript
2023 Q4
28 Feb 24
PSNL
Earnings call transcript
2023 Q3
7 Nov 23
PSNL
Earnings call transcript
2023 Q2
8 Aug 23
PSNL
Earnings call transcript
2023 Q1
3 May 23
PSNL
Earnings call transcript
2023 Q1
3 May 23
PSNL
Earnings call transcript
2022 Q4
23 Feb 23
PSNL
Earnings call transcript
2022 Q3
2 Nov 22
PSNL
Earnings call transcript
2022 Q2
4 Aug 22
PSNL
Earnings call transcript
2022 Q1
5 May 22
PSNL
Earnings call transcript
2021 Q4
25 Feb 22
Latest ownership filings
4
Christopher M Hall
19 Mar 24
4
Aaron Tachibana
19 Mar 24
4
Richard Chen
19 Mar 24
4
Stephen Michael Moore
19 Mar 24
4
WOODROW A MYERS JR
5 Mar 24
4
Richard Chen
31 Jan 24
4
Aaron Tachibana
31 Jan 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Richard Chen
19 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 72.19 mm | 72.19 mm | 72.19 mm | 72.19 mm | 72.19 mm | 72.19 mm |
Cash burn (monthly) | 8.33 mm | 944.17 k | 10.26 mm | 9.84 mm | 5.56 mm | 4.97 mm |
Cash used (since last report) | 56.88 mm | 6.44 mm | 70.05 mm | 67.14 mm | 37.95 mm | 33.90 mm |
Cash remaining | 15.31 mm | 65.75 mm | 2.14 mm | 5.06 mm | 34.24 mm | 38.30 mm |
Runway (months of cash) | 1.8 | 69.6 | 0.2 | 0.5 | 6.2 | 7.7 |
Institutional ownership, Q3 2023
48.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 8 |
Closed positions | 10 |
Increased positions | 10 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 29.34 bn |
Total shares | 24.68 mm |
Total puts | 1.00 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 5.72 mm | $6.92 bn |
JPM JPMorgan Chase & Co. | 3.54 mm | $4.28 bn |
BLK Blackrock | 3.33 mm | $4.03 bn |
Vanguard | 2.07 mm | $2.50 bn |
Alyeska Investment | 1.25 mm | $1.51 bn |
CMTDF Sumitomo Mitsui Trust | 1.08 mm | $1.31 bn |
Nikko Asset Management Americas | 1.08 mm | $1.31 bn |
Wellington Shields Capital Management | 657.74 k | $795.86 mm |
Wellington Shields & Co. | 604.27 k | $731.16 mm |
Renaissance Technologies | 552.48 k | $668.72 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Christopher M Hall | Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 400,000 | 644.00 k | 400,000 |
15 Mar 24 | Richard Chen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 175,000 | 281.75 k | 175,000 |
15 Mar 24 | Tachibana Aaron | Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 175,000 | 281.75 k | 175,000 |
15 Mar 24 | Stephen Michael Moore | Stock Option Common Stock | Grant | Acquire A | No | No | 1.61 | 100,000 | 161.00 k | 100,000 |
1 Mar 24 | Woodrow A Myers JR | Common Stock | Buy | Acquire P | No | No | 1.67 | 10,000 | 16.70 k | 26,116 |
News
Cathie Wood's Ark Laps Up $3.3M Worth Of Tesla As Stock Falls For 3rd Straight Session, Sheds Shares Of This Sports Betting Company
16 Apr 24
Needham Reiterates Buy on Personalis, Maintains $3.5 Price Target
11 Apr 24
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
3 Apr 24
Cathie Wood's Ark Continues Tesla Stock Buying Spree, Acquires Over $14M Worth Of Shares Amid Dip
28 Mar 24
Personalis Announces Publication Validating NeXT Personal Test For Ultra-Sensitive MRD Detection And Cancer Treatment Response Monitoring
26 Mar 24
Press releases
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
26 Mar 24
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Mar 24
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
14 Feb 24
Personalis to Participate at Upcoming Investor Conferences
31 Jan 24